Komori
PhoenixBio (6190) · FactAchieved

Reclassification as convertible bonds with stock acquisition rights due for redemption within one year

First written in FY2023-Q3. 1 of 3 entries say "Achieved", first in FY2024-Q3. Latest entry: FY2024-Q3.

3entries
2years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2023-Q3 – FY20232023: 220232024: 12024
Same theme, other companies
Reclassification of convertible bonds to amounts due for redemption within one yearA theme 3 companies write about · 0 as a headwind · 0 as a tailwind

1 other company's latest entry also says "Achieved".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
  1. FY2024-Q3AchievedAnnual report

    「Taking cash flow into consideration, the company raised ¥500.000 million through bank borrowings, secured sufficient working capital, and redeemed the convertible bonds with share options at maturity on the scheduled date.」

    The ¥875.000 million in convertible bonds with share options classified as due for redemption within one year at the end of the previous consolidated fiscal year was redeemed at maturity on the scheduled date.
  2. FY2023Disclosure of bonds totaling ¥875.000 million due for redemptionAnnual report

    「1st Series Unsecured Convertible Bonds with Share Options (Note) 1 30 March 2020 900,000 875,000 Non-interest-bearing None 29 December 2023」

    The company disclosed a balance of ¥875.000 million in convertible bonds with share options and a redemption date of 29 December 2023.
  3. FY2023-Q3First statedAnnual report

    「This was mainly attributable to a ¥134.023 million decrease in advances received, while convertible bonds with share options due for redemption within one year increased by ¥875.000 million as a result of reclassifications from convertible bonds with share options and other factors, and accrued corporate taxes increased by ¥46.893 million. Non-current liabilities amounted to ¥107.186 million, a decrease of ¥906.361 million from the end of the previous consolidated fiscal year. This was mainly attributable to a ¥900.000 million decrease in convertible bonds with share options due to reclassifications to convertible bonds with share options due for redemption within one year and other factors.」

    Of the ¥900.000 million in convertible bonds with share options, ¥875.000 million was reclassified as due for redemption within one year and recorded as a current liability, which was disclosed as a new fact regarding the company's financial structure.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for PhoenixBio yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.